Sutro Biopharma Financial Statements
Sutro Biopharma Financial Overview
Sutro Biopharma's market cap is currently ―. The company's EPS TTM is $-2.47; its P/E ratio is -1.76; Sutro Biopharma is scheduled to report earnings on August 10, 2022, and the estimated EPS forecast is $-0.66. See an overview of income statement, balance sheet, and cash flow financials.
| Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 5.90M | $ 10.65M | $ 8.52M | $ 28.05M | $ 14.66M |
| Gross Profit | $ ― | $ ― | $ ― | $ ― | $ ― |
| EBIT | $ -38.45M | $ -37.51M | $ -30.08M | $ -5.30M | $ -29.50M |
| EBITDA | $ -37.13M | $ -36.20M | $ -28.96M | $ -4.18M | $ -28.21M |
| Net Income Common Stockholders | $ -39.11M | $ -38.13M | $ -30.90M | $ -6.15M | $ -30.36M |
| Balance Sheet | |||||
| Cash, Cash Equivalents and Short-Term Investments | $ 197.94M | $ 209.15M | $ 229.70M | $ 251.23M | $ 258.70M |
| Total Assets | $ 303.68M | $ 341.41M | $ 371.47M | $ 359.79M | $ 358.53M |
| Total Debt | $ 24.82M | $ 32.11M | $ 34.96M | $ 38.26M | $ 44.40M |
| Net Debt | $ -173.12M | $ -177.04M | $ -194.74M | $ -212.97M | $ -214.31M |
| Total Liabilities | $ 83.30M | $ 88.84M | $ 87.89M | $ 52.29M | $ 51.19M |
| Stockholders Equity | $ 220.37M | $ 244.12M | $ 252.56M | $ 283.58M | $ 307.34M |
| Cash Flow | |||||
| Free Cash Flow | $ -36.81M | $ -24.12M | $ -29.40M | $ -10.68M | $ -32.81M |
| Operating Cash Flow | $ -35.26M | $ -21.58M | $ -24.41M | $ -5.26M | $ -30.43M |
| Investing Cash Flow | $ 32.98M | $ 20.78M | $ -2.24M | $ 5.88M | $ -121.73M |
| Financing Cash Flow | $ 760.00K | $ 506.00K | $ 963.00K | $ -39.00K | $ 1.83M |